
Kynexis extends Series A to €97m to advance cognitive disorder drug
Kynexis has closed a €40 million Series A extension bringing the company’s total Series A financing to €97 million ($110 million). The financing was led by new investor Novartis Venture Fund, with participation from existing investors Forbion, Ysios Capital, and Sunstone Life Science Ventures. In connection with the financing, Novartis… Read More
